Denali Therapeutics Inc. (DNLI) › Operating Cash FlowDenali Therapeutics Inc. (DNLI) — Operating Cash FlowAnnual figures by period end, from SEC filings.2016-12-31: -$71.91M2017-12-31: -$76.64M2018-12-31: $50.12M2019-12-31: -$151.58M2020-12-31: $416.15M2021-12-31: -$211.39M2022-12-31: -$244.72M2023-12-31: -$357.99M2024-12-31: -$347.69M2025-12-31: -$412.60M-$412.60M2016-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$412.60M—2026-02-26From 2025-01-012024-12-31-$347.69M—2026-02-26From 2024-01-012023-12-31-$357.99M—2026-02-26From 2023-01-012022-12-31-$244.72M—2025-02-27From 2022-01-012021-12-31-$211.39M-150.8%2024-02-28From 2021-01-012020-12-31$416.15M—2023-02-27From 2020-01-012019-12-31-$151.58M-402.5%2022-02-28From 2019-01-012018-12-31$50.12M—2021-02-26From 2018-01-012017-12-31-$76.64M—2020-02-27From 2017-01-012016-12-31-$71.91M—2019-03-12From 2016-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)